denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, MDS, Clinical Practice (Health Services and Quality), Non-Biological therapies, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, emerging technologies, Technology and Procedures, profiling, molecular testing, Maternal Health, Pathology
Description:
The therapeutic landscape for Acute Myeloid Leukemia (AML) patients has undergone a remarkable transformation in the past five years. The addition of small molecule inhibitors, such as BCL-2, IDH, and FLT3 inhibitors, have led to increased treatment options and improved outcomes for many patients. However, despite these advancements, the majority of patients will not be cured of their disease. Measurable residual disease (MRD) testing in remission after treatment for AML can identify patients at increased risk of relapse and death. There are also ongoing efforts investigating novel therapeutics for high-risk AML patient subsets to improve current unacceptable poor outcomes. This educational session will examine the current evidence for integrating MRD into response assessments and as a potential treatment goal for patients. The session will also discuss ongoing investigational efforts to improve outcomes in high-risk AML patient subsets such as secondary AML and the genomic subsets: MLL rearranged, FLT3-ITD and TP53 mutated.
Dr. Chris Hourigan will outline the evidence and challenges currently for use of MRD testing in AML to inform treatment decision making and management. Factors such as lack of test harmonization and unclear clinical utility for individual patients have limited widespread adoption of AML MRD testing in clinical practice. He will also discuss the current multiple national-level precision medicine efforts now ongoing to both develop optimal testing and validate AML MRD negativity as a goal of therapy.
Dr. Keith Pratz will present case-based approaches to suggest best practices for current treatment approaches for patients with secondary AML including those with prior chemotherapy exposure or arising from antecedent hematologic malignancy. He will discuss ongoing opportunities and challenges for these high-risk patient populations and ongoing research efforts to improve upon the current poor outcomes of these patients.
Dr. Alice Mims will discuss current ongoing investigational efforts to improve patient outcomes in particular high risk AML molecular subsets: TP53 mutated, MLL or KMT2A rearranged, and FLT3-ITD mutated disease. This talk will examine best current treatment approaches for patients with these specific genomic features along with completed and ongoing research endeavors including novel approaches with immunotherapeutics and targeted small molecule inhibitors.
Dr. Chris Hourigan will outline the evidence and challenges currently for use of MRD testing in AML to inform treatment decision making and management. Factors such as lack of test harmonization and unclear clinical utility for individual patients have limited widespread adoption of AML MRD testing in clinical practice. He will also discuss the current multiple national-level precision medicine efforts now ongoing to both develop optimal testing and validate AML MRD negativity as a goal of therapy.
Dr. Keith Pratz will present case-based approaches to suggest best practices for current treatment approaches for patients with secondary AML including those with prior chemotherapy exposure or arising from antecedent hematologic malignancy. He will discuss ongoing opportunities and challenges for these high-risk patient populations and ongoing research efforts to improve upon the current poor outcomes of these patients.
Dr. Alice Mims will discuss current ongoing investigational efforts to improve patient outcomes in particular high risk AML molecular subsets: TP53 mutated, MLL or KMT2A rearranged, and FLT3-ITD mutated disease. This talk will examine best current treatment approaches for patients with these specific genomic features along with completed and ongoing research endeavors including novel approaches with immunotherapeutics and targeted small molecule inhibitors.